2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 52(2018) N 2 p. 222-231; DOI 10.1134/S0026893317050132 Full Text

Zh.K. Nazarkina1,2*, A. Zajakina3, P.P. Laktionov1,2

Maturation and Antigen Loading Protocols Influence Activity of Anticancer Dendritic Cells

1Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090 Russia
2Meshalkin National Medical Research Center, Ministry of Health of the Russian Federation, Novosibirsk, 630055 Russia
3Latvian Biomedical Research and Study Centre, Riga, LV1067Latvia

Received - 2016-06-15; Accepted - 2016-10-28

The practical use of dendritic cell-based vaccines in anticancer therapy is limited by a lack of standards for dendritic cell (DC) generation, as well as standard procedures for controlling their activation and the technique of DC loading with nucleic acids encoding tumor antigens. Analyzing the currently available data, the most promising cocktails for DC maturation were selected and a comparative study of the cocktails and time of maturation on the capacity of DC to activate T-cell immune response has been performed. A study of the expression of surface markers and the production of IL-12, IL-6, and IL-10 cytokines, as well as the efficacy of T-cell activation showed that the use of the standard 7-day maturation protocol is preferable to the 4-day maturation protocol. Cocktails composed of TNF-α, IL-lβ, IFN-α, IFN-γ, and poly(I:C), as well as TNF-α, IL-lβ, IFN-γ, R848, and PGE2 were shown to be the most efficient activators of DCs. A comparison of the efficacy of different methods of DNA transfection into DCs and RNA delivery using alphavirus vectors demonstrated the superiority of magnet-assisted transfection (MATra) to other protocols.

dendritic cells, antigen delivery, cytotoxic T lymphocytes, anticancer immunotherapy